Astria Therapeutics to Present at Upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference
04 Fevereiro 2025 - 10:00AM
Business Wire
Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical
company focused on developing life-changing therapies for allergic
and immunologic diseases, today announced that Jill C. Milne,
Ph.D., Chief Executive Officer, will participate in a fireside chat
at the upcoming virtual Oppenheimer 35th Annual Healthcare Life
Sciences Conference on Tuesday, February 11th at 10:40am ET.
A webcast of the presentation can be accessed at the following
link: https://wsw.com/webcast/oppenheimer39/atxs/2823424. An
archived replay of the presentation will be available in the
investors section of www.astriatx.com for 30 days following the
event.
About Astria Therapeutics:
Astria Therapeutics is a biopharmaceutical company, and our
mission is to bring life-changing therapies to patients and
families affected by allergic and immunologic diseases. Our lead
program, navenibart (STAR-0215), is a monoclonal antibody inhibitor
of plasma kallikrein in clinical development for the treatment of
hereditary angioedema. Our second program, STAR-0310, is a
monoclonal antibody OX40 antagonist in clinical development for the
treatment of atopic dermatitis. Learn more about our company on our
website, www.astriatx.com, or follow us on Instagram @AstriaTx and
on Facebook and LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20250204912062/en/
Investor Relations and Media: Elizabeth Higgins
investors@astriatx.com
Astria Therapeutics (NASDAQ:ATXS)
Gráfico Histórico do Ativo
De Jan 2025 até Fev 2025
Astria Therapeutics (NASDAQ:ATXS)
Gráfico Histórico do Ativo
De Fev 2024 até Fev 2025
